Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ATF4 | P18848 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489655 | 0.99 | GPR119 (0.47) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL1661798 | 0.81 | GPR119 (0.65) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL1118437 | 0.80 | GPR119 (0.66) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL14139563 | 0.80 | NMT1 (0.39) | KMT2AMEN1TDP1 | |
| SCHEMBL1118325 | 0.80 | GPR119 (0.74) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL1118357 | 0.79 | GPR119 (0.58) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL15340753 | 0.78 | GPR119 (0.49) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL1118435 | 0.76 | GPR119 (0.61) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL1118497 | 0.74 | GPR119 (0.62) | GPR119ALDH1A1KMT2AMEN1ALOX15 | |
| SCHEMBL3489111 | 0.74 | GPR119 (0.46) | GPR119ALDH1A1KMT2AMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2018-01-25 | — | — | US | disclosed |
| US-9737537-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170105993-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150239881-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2280704-B1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8975258-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8921350-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140024830-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
| EP-2111107-B1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8288384-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8227495-B2 | 2,4-disubsituted thiazoles and pharmaceutical compositions thereof | METABOLEX INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100130511-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-04-08 | — | — | US | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | GPR119, GIPR, GLP1R | TACR1 977/4885GPR119 1/4885ALDH1A1 884/4885 |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | GPR119, GLP1R, DPP4 | TACR1 772/4885GPR119 1/4885ALDH1A1 838/4885 |
| US-20140024830-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
| US-20150239881-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | GPR119, GIPR, GLP1R | TACR1 977/4885GPR119 1/4885ALDH1A1 884/4885 |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | TACR1 3422/4885GPR119 3/4885ALDH1A1 1333/4885 |
| US-20170105993-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
| US-20100130511-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | TACR1 91/4885GPR119 1/4885ALDH1A1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.